We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
FUJIREBIO

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

HORIBA Acquires MedTest Dx and Pointe Scientific to Expand Laboratory Chemistry Offerings

By LabMedica International staff writers
Posted on 03 Feb 2021
Print article
Illustration
Illustration
HORIBA, Ltd. (Kyoto, Japan) has acquired MedTest Holdings, Inc. (Canton, MI, USA), composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.).

HORIBA Medical provides an extensive and complete line of hematology and clinical chemistry analyzers (including reagents) for use in In-vitro Diagnostics. MedTest Dx manufactures chemistry reagents and offers diagnostic solutions for decentralized clinical testing, providing a combination of screening instruments and reagent manufacturing in medical technologies, with a wide portfolio of products for IVD testing laboratories. The acquisition will combine the complimentary innovative technology offerings of HORIBA Medical with MedTest Dx technology, Clinitox, and Pointe Scientific's R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.

"Our long term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative Chemistry and Immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest," said Mr. Atsushi Horiba, Chairman & Group CEO of HORIBA, Ltd.

"This acquisition provides HORIBA Medical the opportunity to address the IVD market's multidisciplinary requirements along with the complimentary innovative technology of Pointe Scientific and MedTest's high quality Chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen2 brand and current distribution channels," said HORIBA Medical segment leader Dr. Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.

Related Links:
HORIBA, Ltd.
MedTest Holdings, Inc.


New
Gold Supplier
Tumor Marker Control
Tumor Marker Control
COVID-19 Positive Control
STAT-NAT COVID-19 Positive Control
New
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
SARS-CoV-2 Nucleic Acid Detection Kit
SARS-CoV-2 Nucleic Acid Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.